The weight loss landscape has been transformed by GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and telehealth has become the primary way millions of Americans access these treatments. An estimated 42% of American adults have obesity according to the CDC, and the arrival of medications that can produce 15% to 22% body weight loss has created unprecedented demand. But the surge in demand has also created a crowded market of platforms with wildly different pricing, medical oversight, and legitimacy. Finding the best telehealth for weight loss means understanding what each platform actually offers, what the medications cost, and which approaches are backed by rigorous evidence. For an overview of how virtual care works more broadly, see our telehealth guide.
How Telehealth Weight Loss Programs Work
Most telehealth weight loss platforms follow a similar clinical process. You complete a health assessment covering your weight history, BMI, medical conditions (diabetes, hypertension, sleep apnea, etc.), current medications, previous weight loss attempts, and goals. A licensed provider (physician, nurse practitioner, or physician assistant) reviews your information and conducts a video visit to discuss treatment options, potential risks, and expectations.
If the provider determines you’re a candidate for medication, they prescribe it and send it to a pharmacy or the platform’s own fulfillment pharmacy. For injectable GLP-1 medications, the prescription typically goes to a specialty pharmacy or the platform’s partnered compounding pharmacy, and the medication ships directly to your home.
Ongoing treatment involves monthly follow-up visits to monitor progress, adjust dosages (GLP-1 medications use a titration schedule that gradually increases the dose over several months), manage side effects, review metabolic labs, and provide nutrition and lifestyle guidance. This ongoing monitoring is critical, as GLP-1 medications require dose adjustments and side effect management that shouldn’t be automated.
The clinical criteria for weight loss medication typically include a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. These thresholds align with FDA-approved indications for GLP-1 weight loss medications and the clinical guidelines from the Obesity Medicine Association.
Top Telehealth Weight Loss Platforms
Ro (Ro Body)
Ro’s weight loss program offers GLP-1 medications along with comprehensive medical oversight from a clinical team that includes board-certified obesity medicine physicians. The platform charges a $99 initial consultation fee and $145 per month for ongoing care, which includes monthly provider visits, metabolic lab monitoring (lipids, A1c, thyroid function), and body composition tracking.
Medication costs are separate and vary based on the specific drug and your insurance status. Ro prescribes brand-name GLP-1s (Wegovy, Zepbound) when insurance covers them and helps patients navigate the prior authorization process. For patients paying cash, Ro also offers compounded semaglutide at lower prices, though it’s transparent about the distinction between FDA-approved brand-name medications and compounded alternatives.
Ro’s medical team includes providers credentialed in obesity medicine, which adds clinical rigor beyond what general telehealth platforms offer. The program also includes nutrition coaching, behavioral support, and educational content designed to support the lifestyle changes that complement medication. Ro’s approach reflects the medical consensus that medication works best as part of a comprehensive weight management strategy.
Calibrate
Calibrate positions itself as a metabolic health program rather than a simple prescription pipeline. The program costs approximately $159 per month (billed annually at roughly $1,900) and includes GLP-1 medication management, a dedicated one-on-one coach, a structured food and exercise curriculum based on metabolic science, sleep optimization guidance, and ongoing metabolic lab monitoring.
Calibrate accepts some insurance for the medication component and works aggressively to obtain prior authorization for GLP-1 prescriptions. The company reports a high success rate in getting insurance approval, which can save patients thousands of dollars on medication costs. The program is designed as a 12-month commitment, reflecting extensive research showing that sustained weight loss requires long-term behavioral change alongside medication.
The emphasis on behavioral change alongside medication is important. According to a landmark study published in the New England Journal of Medicine, patients who discontinued semaglutide regained approximately two-thirds of their lost weight within a year. Programs like Calibrate that build habits and accountability around food, exercise, and sleep are designed to improve long-term outcomes even if medication is eventually discontinued.
Found
Found offers a broader medication approach than GLP-1-only platforms, which can be an advantage for patients who don’t qualify for or can’t afford injectable medications. Starting at approximately $99 per month for the program fee (medication costs extra), Found’s providers may prescribe metformin, bupropion-naltrexone (Contrave), topiramate, phentermine (short-term), or GLP-1 medications depending on your medical profile and goals.
This multi-medication approach is clinically sound. Not every patient is a candidate for GLP-1 medications, and some may respond well to less expensive alternatives. Metformin, for example, costs as little as $4 per month with a GoodRx coupon and has modest weight loss benefits (5% to 7% of body weight) along with metabolic improvements. Bupropion-naltrexone (Contrave) can produce 5% to 10% weight loss and also addresses food cravings. For patients whose primary barrier is insurance coverage for GLP-1s, Found’s alternative medication options provide a meaningful path forward.
Found also offers coaching and community support, though the program is less structured than Calibrate’s year-long curriculum. The platform works well for patients who want medical guidance and prescription access without the higher price tag of premium programs.
Hims/Hers
Hims and Hers (the men’s and women’s health platforms, respectively) have aggressively entered the weight loss market with compounded GLP-1 medications at lower prices than brand-name alternatives. Programs start at approximately $79 per month for the medical consultation, plus medication costs starting around $199 per month for compounded semaglutide, significantly less than brand-name Wegovy’s list price of over $1,300 per month.
The lower medication cost is the primary draw. However, patients should understand an important distinction: compounded semaglutide and tirzepatide are not FDA-approved finished products. They are produced by compounding pharmacies under the FDA’s drug shortage provisions, which allow compounding of certain medications when the FDA-approved versions are in shortage. The FDA has raised concerns about the quality, sterility, and dosing consistency of compounded GLP-1 medications, and the legal authority to compound these drugs may change if shortages resolve.
For patients who cannot afford brand-name GLP-1 medications and don’t have insurance coverage, compounded versions through Hims/Hers represent an accessible, if legally and quality-uncertain, option. Patients should discuss the trade-offs with their provider and understand that the long-term availability of compounded GLP-1 medications is not guaranteed.
Insurance-Based Options
If your insurance covers weight loss treatment, starting with your insurer’s telehealth platform may be the most affordable overall path. UnitedHealthcare, Aetna, and Cigna all cover obesity management visits through telehealth, with copays typically ranging from $20 to $75 per session.
The challenge is getting GLP-1 medications covered. Many insurers require prior authorization, step therapy (trying cheaper medications or documented lifestyle interventions first), and documentation of BMI plus comorbidities. The prior authorization process can take 1 to 4 weeks and may require appeals. However, when approved, insurance can reduce GLP-1 medication costs from over $1,000 per month to $0 to $150 per month, making the administrative effort worthwhile.
Understanding GLP-1 Medication Costs
Medication cost is the single biggest variable in telehealth weight loss programs. Here’s the pricing landscape as of 2026:
- Wegovy (semaglutide 2.4mg weekly injection): $1,300 to $1,500/month list price; $0 to $250/month with commercial insurance; not covered by Medicare
- Zepbound (tirzepatide weekly injection): $1,000 to $1,200/month list price; $0 to $250/month with commercial insurance; not covered by Medicare
- Compounded semaglutide: $199 to $499/month (not FDA-approved as a finished product; availability may change)
- Compounded tirzepatide: $299 to $599/month (same caveats as compounded semaglutide)
- Metformin (generic): $4 to $15/month
- Contrave (bupropion-naltrexone): $99 to $250/month; limited insurance coverage
- Phentermine (generic, short-term use): $10 to $30/month
Insurance coverage for GLP-1 weight loss medications remains inconsistent. Medicare currently does not cover anti-obesity medications, though the Treat and Reduce Obesity Act has been reintroduced in Congress to change this. Commercial insurance coverage varies widely by employer and plan, with some large employers adding GLP-1 coverage and others explicitly excluding it due to cost concerns. Understanding your specific coverage is critical before committing to a platform or medication. Our healthcare costs guide provides broader context on navigating out-of-pocket medical expenses.
What the Evidence Says
GLP-1 medications represent the most significant advance in obesity treatment in decades. Clinical trials published in the New England Journal of Medicine provide robust evidence:
Semaglutide 2.4 mg (Wegovy): The STEP 1 trial showed average weight loss of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% over two years of continued treatment.
Tirzepatide (Zepbound): The SURMOUNT-1 trial showed dose-dependent weight loss of 15% to 22.5% of body weight at the highest dose over 72 weeks, making it the most effective obesity medication ever studied. More than one-third of participants lost over 25% of their body weight.
However, these results come with important caveats. Weight regain after discontinuation is significant, with the STEP 1 extension study showing that patients regained approximately two-thirds of lost weight within a year of stopping semaglutide. This suggests that GLP-1 medications may need to be taken long-term for sustained benefit, similar to blood pressure or cholesterol medications.
Side effects, primarily gastrointestinal (nausea, vomiting, diarrhea, constipation), affect 40% to 70% of patients, though they typically diminish over time and can be managed through gradual dose titration. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid concerns (based on animal studies). Long-term safety data beyond 5 years is still being collected. Patients should discuss these risks thoroughly with their provider before starting treatment.
Red Flags to Avoid
The weight loss telehealth market has attracted predatory operators alongside legitimate providers. Be wary of platforms that prescribe medication without a thorough medical evaluation (including review of your medical history, current medications, and contraindications), don’t require regular follow-up visits for monitoring, sell compounded medications as equivalent to FDA-approved products without explaining the differences, guarantee specific weight loss results, or charge excessively for services that consist of a brief questionnaire and minimal provider interaction.
Legitimate platforms conduct comprehensive medical assessments, require ongoing monitoring (monthly visits during dose titration, quarterly once stable), discuss both benefits and risks openly, include lifestyle modification support, and involve licensed providers who have training or certification in obesity medicine or a related field. The Obesity Medicine Association maintains a directory of board-certified obesity medicine specialists.
Frequently Asked Questions
Can I get Ozempic through telehealth?
Some telehealth platforms can prescribe semaglutide, the active ingredient in both Ozempic and Wegovy. Ozempic is technically FDA-approved only for type 2 diabetes, while Wegovy is the FDA-approved weight loss formulation at a higher dose. Your provider will determine which medication and formulation is appropriate based on your medical history and insurance coverage.
How much does telehealth weight loss cost per month?
Total monthly costs (program fee plus medication) range from about $100 to $150 per month for non-GLP-1 approaches (metformin, Contrave) to $300 to $650 per month for programs with compounded semaglutide. Brand-name GLP-1 medications without insurance can push total costs above $1,500 per month. With insurance covering the medication, total costs drop to $100 to $300 per month including the program fee.
Does insurance cover telehealth weight loss programs?
Most insurance plans cover the telehealth consultation component of weight loss treatment (the provider visit). Medication coverage varies significantly. Many commercial plans now cover GLP-1 medications for weight loss with prior authorization, though step therapy requirements may apply. Medicare does not currently cover anti-obesity medications. Contact your insurer before starting treatment to understand your specific coverage.
Are compounded GLP-1 medications safe?
Compounded semaglutide and tirzepatide are produced by compounding pharmacies under FDA drug shortage provisions and are not FDA-approved finished products. The FDA has warned about quality, sterility, and dosing consistency concerns. Some patients use compounded versions without incident, but they carry more regulatory and quality uncertainty than FDA-approved brand-name medications. The availability of compounded GLP-1 medications may change if drug shortages resolve. Discuss the specific risks with your provider.
Will I regain weight if I stop GLP-1 medication?
Clinical evidence suggests that significant weight regain is common after discontinuing GLP-1 medications. The STEP 1 extension study showed approximately two-thirds of lost weight was regained within a year of stopping semaglutide. This is why comprehensive programs that include behavioral modification, nutrition counseling, and exercise support are valuable: building sustainable habits may reduce the degree of regain even if medication is eventually discontinued.
What to Do Next
Before choosing a platform, check whether your insurance covers GLP-1 medications for weight loss by calling the pharmacy benefits number on your insurance card. If coverage is available, working with your insurer’s telehealth program or an in-network obesity medicine provider may be the most affordable path. If you’re paying cash, compare total monthly costs (program fee plus medication) across platforms rather than focusing on the consultation fee alone. Ask about the provider’s credentials in obesity medicine, the frequency of follow-up visits, what happens if the medication isn’t working, and whether the program includes behavioral support alongside prescribing. Sustainable weight loss is a marathon, and the platform you pick should be built for long-term medical partnership, not a quick transaction.